Title |
Future possibilities in the prevention of breast cancer: Breast cancer prevention trials
|
---|---|
Published in |
Breast Cancer Research, August 2000
|
DOI | 10.1186/bcr66 |
Pubmed ID | |
Authors |
Jack Cuzick |
Abstract |
The available results from breast cancer chemoprevention trials are reviewed. Four trials using tamoxifen have been performed, of which three have reported efficacy results. A fifth trial using raloxifene has also been reported. The largest tamoxifen trial showed approximately 50% reduction in breast cancer incidence in the short term, but the two smaller trials did not find any reduction. Greater agreement exists for side effects; incidences of thromboembolic disease and endometrial cancers are raised approximately threefold when tamoxifen is used for 5 years. The possible reasons for the discrepancy in breast cancer reduction are explored. A review of trial parameters does not clearly explain this difference, and a meta-analysis indicates that all results are compatible with a 40% reduction in short-term incidence. Several important questions remain regarding the clinical implications of this result, including the effect on mortality, the appropriate risk groups for chemoprevention and the long-term effects on incidence. Continued follow up of these trials is crucial for resolving these issues. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 30 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 6 | 20% |
Student > Master | 5 | 17% |
Student > Bachelor | 4 | 13% |
Professor > Associate Professor | 3 | 10% |
Student > Ph. D. Student | 2 | 7% |
Other | 6 | 20% |
Unknown | 4 | 13% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 15 | 50% |
Nursing and Health Professions | 3 | 10% |
Psychology | 3 | 10% |
Agricultural and Biological Sciences | 2 | 7% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 7% |
Other | 1 | 3% |
Unknown | 4 | 13% |